Digital pathology opportunity 3Scan’s core offering of digital and computational pathology with high-throughput KESM tissue imaging positions it as a partner for labs and pharma teams seeking scalable histology data, enabling faster biomarker discovery and more efficient preclinical studies.

3D tissue data The capability to produce digital 3D tissue models at micron-scale resolution and 400x throughput suggests strong cross-sell potential into institutions pursuing spatial omics, advanced diagnostics, or AI-driven pathology workflows.

Strategic partnerships Past collaborations with UPMC and a merger with Transcriptic indicate openness to ecosystem partnerships, automation, and cloud-enabled data platforms, opening doors for co-developed solutions with academic centers and contract research organizations.

Financial strength With reported revenue in the low seven figures and $21M in funding, 3Scan has runway for technology development, pilot programs, and expansion into new markets, making it a viable partner for enterprise pilots and trial deployments.

Technology stack fit Reliance on scalable cloud and analytics stack (AWS, Google Workspace, data analytics) aligns with enterprise buyers seeking secure, interoperable digital pathology platforms, enabling easy integration with existing IT and data science workflows.